3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Myeloproliferative Disorders
1
Interventions
ruxolitinib
3
venetoclax
1
veliparib
1
pevonedistat
1
navitoclax
1
givinostat hydrochloride
1
givinostat
1
fludarabine phosphate
1
bomedemstat
1
anagrelide
1
Whole-Body Irradiation
1
Valganciclovir
1
Topotecan
1
Therapeutics
1
Tacrolimus
1
Sirolimus
1
Polymerase Chain Reaction
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
INCB057643
1
Ganciclovir
1
Foscarnet
1
Flow Cytometry
1
Etoposide
1
Drug Evaluation
1
Cyclosporine
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Thrombocythemia, Essential
×
anagrelide
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled